Structured health knowledge, clearly mapped.Evidence-aware · Reader-first · Mobile-ready
HealthnivozAnatomy of Better Health
Atlas→HEALTH→Reference Plate
Region · HEALTHHealthnivoz Reference Plate

Reading a Pipeline Chart: What Companies Show and What They Leave Out

Nearly every pharmaceutical company presents a pipeline chart, a graphic that places each development program on a timeline from early research to approval. These charts appear straightforward, but the way they are drawn can…

Plate72
Session2 min
RegionHEALTH
UpdatedNov 2026
the reporting from The Pharma VanguardHEALTHFig. 171
Structured Guide

Nearly every pharmaceutical company presents a pipeline chart, a graphic that places each development program on a timeline from early research to approval. These charts appear straightforward, but the way they are drawn can emphasize progress and conceal setbacks, so reading them critically is a useful investor skill.

The first thing to check is what has disappeared. Programs that were listed in earlier presentations and are now missing may have been discontinued, and comparing successive versions of the chart often shows more about a company’s research productivity than any single version does.

Phase labels deserve scrutiny. A program described as being in a given phase may be a single small study rather than a full program, and a drug listed in multiple indications can look like a broad portfolio when most of those indications are early and unproven. The number of programs matters less than the number of well-supported ones.

Timelines are projections, not commitments. Expected dates for data and filings frequently slip, and a pattern of repeated delays across several programs may indicate operational difficulty or optimistic planning. Tracking whether a company has met its previously stated dates provides a record of reliability.

Probability of success should be applied independently. Industry-wide, the share of drugs that move from early clinical testing to approval is low, with oncology and neurology historically lower than some other areas. A chart filled with early-stage programs reflects potential rather than expected outcomes.

Concentration is another consideration. A company whose pipeline relies on one or two late-stage assets carries more risk than one with several independent programs, since a single failure can alter its prospects substantially.

A useful exercise is to count programs by stage and apply historical advancement rates to estimate how many might reach approval. The result is typically far smaller than the number of items on the chart suggests, and the exercise shows how much of a company’s value depends on a few late-stage assets. Doing this for several peers side by side reveals which firms have deep pipelines and which have a handful of hopeful bets. A company that reports its own historical success rate honestly, including failures, usually deserves more credibility than one that shows only wins.

Analysis that compares successive pipeline charts, checks stated timelines against actual events, and applies realistic attrition rates, such as the reporting from The Pharma Vanguard, gives readers a more honest picture than the presentation slide alone.

Clinical Reader Note

This material is educational and is not a substitute for professional medical advice, diagnosis, or treatment.